In their review article on the polycystic ovary syndrome, McCartney and Marshall (July 7 issue) did not address the topic of nonalcoholic fatty liver disease. Several studies have recently shown that the prevalence of nonalcoholic fatty liver disease is markedly increased among women with the polycystic ovary syndrome, independent of overweight or obesity and other coexisting components of the metabolic syndrome, and that these women are more likely to have the more severe forms (nonalcoholic steatohepatitis, advanced fibrosis, and cirrhosis).2 Accumulating evidence also suggests that nonalcoholic fatty liver disease exacerbates hepatic and peripheral insulin resistance, confers a predisposition to atherogenic dyslipidemia, and causes the release of several proinflammatory, procoagulant, and profibrogenic mediators that may play important roles in the pathophysiology of the polycystic ovary syndrome and its related complications (principally cardiovascular disease and diabetes). These findings call for a more active and systematic search for nonalcoholic fatty liver disease in patients with the polycystic ovary syndrome.

Polycystic Ovary Syndrome

TARGHER, Giovanni
2016-01-01

Abstract

In their review article on the polycystic ovary syndrome, McCartney and Marshall (July 7 issue) did not address the topic of nonalcoholic fatty liver disease. Several studies have recently shown that the prevalence of nonalcoholic fatty liver disease is markedly increased among women with the polycystic ovary syndrome, independent of overweight or obesity and other coexisting components of the metabolic syndrome, and that these women are more likely to have the more severe forms (nonalcoholic steatohepatitis, advanced fibrosis, and cirrhosis).2 Accumulating evidence also suggests that nonalcoholic fatty liver disease exacerbates hepatic and peripheral insulin resistance, confers a predisposition to atherogenic dyslipidemia, and causes the release of several proinflammatory, procoagulant, and profibrogenic mediators that may play important roles in the pathophysiology of the polycystic ovary syndrome and its related complications (principally cardiovascular disease and diabetes). These findings call for a more active and systematic search for nonalcoholic fatty liver disease in patients with the polycystic ovary syndrome.
2016
NAFLD, PCOS
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/949904
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 3
social impact